The conversation discusses using Shatavari, an Ayurvedic treatment, for hair loss. Other treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.
The conversation is a humorous and hopeful prayer for the effectiveness of finasteride in combating hair loss. Participants express gratitude and support for the treatment.
Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
A user is trying Ayurvedic remedies for male pattern baldness, including onion juice, curry leaves, aloe vera, and a prepared oil mix. They plan to switch to minoxidil, finasteride, and PRP treatment if no improvement is seen in four months.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Ashwagandha topical formulation may increase hair density and reduce hair loss, but results seem too good to be true due to a small sample size. Users are skeptical about its effectiveness and are experimenting with different application methods.
A user humorously discusses hair loss, using treatments like Dutasteride, Finasteride, Minoxidil, and RU58841, and jokingly considers satanic rituals as a solution. The conversation includes satirical responses about trading one's soul for hair.
Finasteride and Ashwagandha are discussed as potential treatments for hair loss, with mixed opinions on Ashwagandha's effectiveness and safety. Some users report no benefits from Ashwagandha, while others caution against its use due to potential liver issues.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
The conversation is about hair loss treatments, specifically setipiprant, which the user is considering after experiencing side effects from finasteride and dutasteride. Another user mentions that setipiprant was ineffective in clinical trials.
Ashwagandha may help with hair loss by regulating thyroid function and reducing stress, but its effectiveness compared to finasteride or minoxidil is debated. Some users report positive effects on hair health, while others are skeptical of its benefits.
The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
The conversation is about using topical valproic acid (VPA) for hair loss, focusing on its application method, usage frequency, and combination with other treatments like micro-needling. No specific experiences with VPA were shared.
The post discusses the impact of Ashwagandha on hair loss, highlighting its ability to lower stress levels, which is beneficial for hair health. However, there's uncertainty about its potential to increase testosterone and DHT, which could contribute to hair loss.
The conversation discusses concerns about using Ashwagandha with Dutasteride for hair loss, as Ashwagandha may increase testosterone and potentially affect DHT levels. Users generally agree that the increase in DHT is minimal and unlikely to impact the effectiveness of Dutasteride significantly.
A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
The conversation is a satirical discussion about hair loss treatments, with users joking about immediate and exaggerated results from finasteride, dutasteride, and other treatments like microneedling and minoxidil. Some users mock concerns about side effects and the idea of posting rapid progress updates.